Conference Day One |
Wednesday, December 3

8:00 am Check-In & Coffee

8:50 am Chair’s Opening Remarks

Elevating Real-World Evidence Through Targeted Data Quality Innovation & Governance to Drive Trusted, Actionable Insights

9:00 am Enhancing Trust in Digital RWD by Tackling Attribution & Engagement- Driven Data Quality Issues

  • Dario Motti Head of Digital Health Evidence Hub, Takeda Pharmaceutical

Synopsis

  • Exploring the unique quality challenges arising from digital health tools, including unclear data attribution and user engagement variability
  • Understanding how new RWD sources complicate trust in clinical meaning and the implications for downstream evidence generation
  • Discussing solutions such as enhanced metadata tracking, attribution protocols, and user-centric data design to improve reliability

9:30 am Integrating RWE-Derived Counterfactuals into Oncology Trials: Rethinking Crossover Design

  • Ankita Kaushik Global Senior Director - HEOR, Value & Access, Gilead Sciences

Synopsis

  • Examine how crossover designs are being increasingly adopted in oncology to provide treatment access while preserving trial integrity
  • Explore the use of real-world evidence to construct counterfactual comparisons for patients who switch arms, enabling more robust treatment effect estimation
  • Discuss methodological and regulatory considerations for integrating RWE-derived counterfactuals into clinical trial endpoints and analyses

10:00 am Speed Networking

Synopsis

This session is a great opportunity to introduce yourself to the attendees that you would like to

have more in depth conversations with. This session is the ideal opportunity to get face-to-face

time with many of the real-world evidence experts to establish meaningful business relationships.

10:30 am Morning Break

11:00 am Power of Real-World Evidence in Personalized Healthcare in Oncology

  • Qing Zhang Senior Principal Data Scientist, Genentech

Synopsis

  • Real-world comparative effectiveness of first-line alectinib versus crizotinib in patients with advanced ALK-positive NSCLC
  • Conditional approval of FoundationOne®CDx as a Companion Diagnostic for Rozlytrek® (entrectinib)
  • Real-world OS in patients with aNSCLC with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations

Advancing AI & Digital Health Application to Enhance Evidence Generation

11:30 am Machine Learning Meets Real-World Data: Unlocking Better Insights in Healthcare

  • Gurleen Jhuti Head of Technical Institute, Policy, Evidence and Access Strategy, Genentech

Synopsis

  • Explore how machine learning can be applied to real-world data to predict patient outcomes and uncover hidden patterns in clinical and economic trends
  • Assess the potential for ML to complement—or even challenge—traditional health economics methodologies
  • Discover how integrating ML into automated insights dashboards can accelerate decision-making and deliver more personalized, scalable healthcare insights

12:00 pm Lunch & Networking Break

1:00 pm Unlocking Precision & Predictive Power with Genetic Data in Real-World Evidence

  • Nicole Miller Molecular Diagnostics Professional, Ultragenyx Pharmaceutical Inc.

Synopsis

  • Improve patient stratification and treatment targeting by integrating genetic insights into RWE projects
  • Enhance the predictive value of real-world studies through deeper biological context and mechanistic understanding
  • Navigate data quality, privacy, and integration challenges to maximize the value of genomic data in evidence generation

Navigating Cross-Functional Collaboration to Improve Effectiveness of RWE Studies

1:30 pm Panel: Enhancing Stakeholder Engagement by Communicating RWE Findings in Clear, Purpose-Driven Language

  • Hairong Xu Executive Director - Global Medical Affairs & Clinical Development, Kite Pharma Inc
  • Elizabeth Timberlake Kinter Vice President & Head of Global Market Access, Avidity Biosciences
  • Natalia Sadetsky Senior Director - Real World Evidence, Gilead Sciences
  • Matthew Dean Executive Director - Value, Access, Pricing, Patient Services & Policy, Nuvation Bio

Synopsis

  • Demonstrating how to adapt scientific outputs for non-technical audiences including providers, payers, and policy influencers
  • Balancing nuance and clarity: ensuring analytical complexity is preserved while maintaining audience accessibility
  • Showcasing communication models that increase trust, transparency, and impact of RWE at critical decision points

2:00 pm Afternoon Break & Poster Session

Synopsis

Witness some of the latest and greatest research in the RWE and evidence generation field by

pharma, biotech, and service providers in this spotlight poster session! For more information or to

submit your abstract, please email info@hansonwade.com

3:00 pm Roundtable: Improving Evidence Credibility by Overcoming Emerging Data Quality Challenges

Synopsis

  • Examining the persistent impact of poor data quality on value delivery and long-term stakeholder trust in real-world insights
  • Identifying common quality pitfalls including missing data, unstandardized reports, and inconsistent integration across traditional sources
  • Outlining industry strategies to move from reactive fixes to proactive data governance and quality-by-design approaches

3:30 pm Applying Pragmatic Trial Design to Bridge the Gap Between Research & Practice

  • Laura Housman Senior Vice President & Director - Practice Evidence & Strategy, Avalere Health

Synopsis

  • Demonstrating how pragmatic trials generate highly generalizable evidence while preserving scientific rigour
  • Identifying when pragmatic design is best suited over traditional RCTs in real-world settings
  • Discussing operational considerations including site selection, protocol flexibility, and endpoint relevance

4:00 pm Chair’s Closing Remarks